Peptide oral strip manufacturing process: Process Controls and Acceptance Criteria

Translate the keyword into a target product profile

The first technical task is to translate the keyword into measurable product requirements. For peptide oral strip manufacturing process, the brief should identify peptide sequence or commercial name, molecular form, counterion, source, purity, assay basis, proposed amount per strip, daily use, target market and intended statements. Those inputs determine whether laboratory screening is meaningful and whether the project belongs on a food-supplement, research or medicinal pathway.

Technical feasibility factors

A scalable process controls solids concentration, viscosity, deaeration, coating gap, web speed, drying zones, residual moisture, slitting registration and sachet seals. Each control should connect to a critical quality attribute rather than exist as an isolated machine setting.

Representative finished-product testing may include identity, assay, unit uniformity, dimensions, mass, thickness, disintegration, moisture, microbial quality and seal integrity. The exact specification depends on classification and risk.

Quality evidence to request

Supplier documentation is useful only when it matches the lot, method and proposed use. Request the peptide specification, certificate of analysis, test methods, impurity information, origin and storage conditions. For the finished film, define sampling and acceptance criteria before scale-up.

• Raw-material identity and assay on an appropriate basis
• Uniformity strategy across the mixed mass, cast web and cut units
• Moisture, appearance, mechanical handling and disintegration controls
• Packaging seal verification and stability-indicating observations
• Deviation, change-control and traceability records

Regulatory and claims boundary

Claims must follow the product’s legal category. In the United States, dietary-supplement structure/function claims require substantiation and must not become disease claims. New dietary ingredient questions may also require premarket work. In the European Union, novel-food status and the authorized-claims framework require separate review.

Neither “sublingual” nor “needle free” automatically establishes a permitted claim. If the commercial proposition depends on systemic delivery, treatment, pharmacological action or equivalence to a drug, the project needs specialist drug-regulatory and clinical assessment.

Questions to put in the RFQ

1. Which process parameters are treated as critical?
2. How is coating mass translated into unit dose?
3. How are edge, wrinkle, bubble and registration defects controlled?
4. Which records support lot release and traceability?

Use a decision gate before formulation begins

A short gate review can prevent expensive prototype work. Confirm material identity, target market, intended claims, feasible dose range, analytical approach and whether the project belongs on a supplement, research or medicinal pathway before ordering custom packaging.

A practical development sequence

1. Define the target product profile and critical quality attributes.
2. Link mixing, casting, drying and cutting parameters to those attributes.
3. Qualify sampling and test methods at pilot scale.
4. Lock specifications, records and deviation controls before routine manufacture.

Technical deep dive for this project brief

Polymer selection

Film-forming polymers determine viscosity, castability, strength, disintegration and mouthfeel. Selection should consider grade, molecular weight, supplier variability and ionic interactions. A polymer that works for a vitamin strip may not remain suitable after adding a peptide material.

Scale-up comparability

Scale-up changes surface area, mixing energy, coating width, drying history and residence time. A comparability plan should define which attributes and process data must remain aligned between the approved pilot and the commercial lot.

Plasticizer balance

Plasticizer can improve flexibility but may also increase tack, moisture uptake or migration. The useful range should be evaluated after conditioning and in the proposed package, because an initially flexible strip can change as water redistributes over time.

Change control

Peptide supplier, synthesis route, salt form, polymer grade, flavor, laminate or process parameter changes can alter risk. The quality agreement should define notification timing, data expectations and which changes require revalidation or new stability work.

Frequently asked questions

Related development resources

Review our Peptide Oral Strips development page, oral strip product matrix, OEM/ODM services and feasibility inquiry form.

Authoritative references

• FDA: Structure/Function Claims
• FDA: Dietary Supplement CGMPs
• ICH Q1A(R2): Stability Testing
• Review: Orally disintegrating film formulation and manufacturing

Request a Peptide Strip Feasibility Review